Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2015

View Archived Issues

Sato and Pola Pharma to comarket topical agent for tinea unguium

Nivolumab in esophageal cancer

First-in-class PFKFB4 inhibitor suppresses tumor growth in mice

Serum microRNAs revealed as potential biomarkers for diabetes

Glucokinase regulatory protein may be associated with PCOS

Pfizer acquires Nimenrix and Mencevax from GlaxoSmithKline

FDA accepts Jazz Pharmaceuticals' NDA for defibrotide in hepatic veno-occlusive disease

Progentec and OMRF enter collaboration to develop autoimmune diagnostic tests

Generex to acquire controlling share of Hema Diagnostic Systems

Karolinska Development divests holding in XSpray Microparticles

Kura initiates new phase II trial of tipifarnib in peripheral T-cell lymphoma

PD/PK of topoisomerase inhibitor ACT-387042

Mitsubishi Tanabe licenses rights to Regeneron's fasinumab

Combination of repurposed antidepressants induces autophagy in glioma cells

Otsuka files NDA in Japan for carteolol/latanoprost for glaucoma

FDA awards orphan drug designation to RGX-111 for MPS I

Beijing Hanmi divulges ROR-gamma receptor antagonists

Boehringer Ingelheim discloses SYK inhibitors

NIH awards two grants to OptiKira

Roche and Genentech patent Pim kinase inhibitors

Pfizer introduces DGAT-2 inhibitors

Hinova reports deuterated PARP inhibitors

Allergan adds to esthetics assets with Kythera acquisition

FDA accepts Sandoz BLA for biosimilar etanercept

Biotron releases interim data from phase II study of BIT-225 in HCV

New company Neon Therapeutics to develop neoantigen-based cancer immunotherapies

EMA accepts Ultragenyx's MAA for aceneuramic acid prolonged release

Kaken files application for approval of periodontal regenerative agent KCB-1D

FDA approves Keytruda and companion diagnostic for PD-L1-expressing NSCLC tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...